# Isomorphic Labs

> AI-first pharmaceutical research company combining molecular design models, pharma collaborations and an internal therapeutic pipeline.

## Why it is interesting

Its May 2026 $2.1B Series B is among the largest disclosed AI-drug-discovery startup rounds; the key question is whether molecular design leads to validated medicines and repeatable partnership economics.

## Profile

- **Latest funding:** Series B — $2.1B new equity funding (May 12, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** $2.1B
- **Stage:** growth
- **Status:** private
- **Industries:** biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund

## Funding history

- Series B · $2.1B new equity funding · May 12, 2026
  Source: https://www.isomorphiclabs.com/press/isomorphic-labs-funding

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/isomorphic-labs